🚨 Bioverge Access Fund 4 is now accepting investors! Leverage Bioverge expertise and back 15 leading healthcare startups through a single investment. Learn more and invest
Qajwctxbtp9qegxhehbw

Impact Investing: Healthcare Startups vs The Stock Market

For retail investors, it has only become possible to invest in startups and private companies over the last 1-2 decades. This is largely the result of new legislation like Regulation CF and the proliferation of startup investing platforms. Prior to this, only well-connected investors with a significant net worth had the opportunity to invest in these companies.

continue reading >
Yieyxrsfsiycizcbnuds

The Bioverge Podcast: Evolving Failures in an Evolving Pandemic and What Needs to Be Done

Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.

continue reading >
Wfajhg7jquawlzel0nf1

The Bioverge Podcast: Democratizing Entrepreneurship

Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discuss OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.

continue reading >
C1kwmrursjxxjs082znw

Healthcare-Focused Impact Investing: Another Way To Invest For Change

Healthcare provides another avenue in which investors can do well by doing good.

continue reading >
16jqvvtoc2djv2ggjliw

Enveda Investment Thesis

Bioverge recently invested in Enveda’s $51 million Series A led by Lux Capital.  Enveda is biotechnology startup focused on harnessing the power of nature’s chemistry to develop next generation small-molecule therapeutics.

continue reading >
Obols5votkmhh1nfaocj

Managed marketplaces and reality TV: How a new generation of gatekeepers is opening biotech up to amateur investors

Starton Therapeutics, a drug delivery biotech, is raising its next round of capital through Unicorn Hunters, a streaming show that invites viewers to consider and invest in a variety of startups alongside a panel of celebrity investors.

continue reading >
1g9vsocptzevfhfskitq

The Bioverge Podcast: Why the FDA Was Right to Approve Biogen's Aduhelm

James Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.

continue reading >
C6jfl3hhtiohykcygh7t

Juno Diagnostics Investment

Juno Diagnostics, a San Diego based genetic diagnostics company in the Bioverge portfolio, just raised a $25 million Series A round led by Perceptive Xontogeny Venture Fund in May 2021.

continue reading >
Bkect61tqqoepbcvxb2j

The Bioverge Podcast: Managing the Challenges of Scaling Cell and Gene Therapies

Amy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.

continue reading >
Qajwctxbtp9qegxhehbw
Investing

Impact Investing: Healthcare Startups vs The Stock Market

For retail investors, it has only become possible to invest in startups and private companies over the last 1-2 decades. This is largely the result of new legislation like Regulation CF and the proliferation of startup investing platforms. Prior to this, only well-connected investors with a significant net worth had the opportunity to invest in these companies.

Continue Reading >
Yieyxrsfsiycizcbnuds
Media

The Bioverge Podcast: Evolving Failures in an Evolving Pandemic and What Needs to Be Done

Dr. Eric Topol, founder and director of the Scripps Research Translational Institute, sits down with Neil to discuss the COVID-19 delta variant, our failures to evolve with the virus, and what steps need to be taken to combat the ongoing pandemic.

Continue Reading >
Wfajhg7jquawlzel0nf1
Media

The Bioverge Podcast: Democratizing Entrepreneurship

Juan Scarlett, managing director of OneValley Ventures, sits down with Neil to discuss OneValley's efforts to democratize entrepreneurship and his approach investing in pre-seed and seed funding rounds.

Continue Reading >
C1kwmrursjxxjs082znw
Investing

Healthcare-Focused Impact Investing: Another Way To Invest For Change

Healthcare provides another avenue in which investors can do well by doing good.

Continue Reading >
16jqvvtoc2djv2ggjliw
Investing

Enveda Investment Thesis

Bioverge recently invested in Enveda’s $51 million Series A led by Lux Capital.  Enveda is biotechnology startup focused on harnessing the power of nature’s chemistry to develop next generation small-molecule therapeutics.

Continue Reading >
Obols5votkmhh1nfaocj
Press

Managed marketplaces and reality TV: How a new generation of gatekeepers is opening biotech up to amateur investors

Starton Therapeutics, a drug delivery biotech, is raising its next round of capital through Unicorn Hunters, a streaming show that invites viewers to consider and invest in a variety of startups alongside a panel of celebrity investors.

Continue Reading >
1g9vsocptzevfhfskitq
Media

The Bioverge Podcast: Why the FDA Was Right to Approve Biogen's Aduhelm

James Valentine, an attorney with Hyman, Phelps & McNamara specializing in regulatory law, sits down with Neil to discuss the FDA’s accelerated approval of Biogen’s Aduhelm for Alzheimer’s disease and offers a contrarian take on the controversy.

Continue Reading >
C6jfl3hhtiohykcygh7t
Startups

Juno Diagnostics Investment

Juno Diagnostics, a San Diego based genetic diagnostics company in the Bioverge portfolio, just raised a $25 million Series A round led by Perceptive Xontogeny Venture Fund in May 2021.

Continue Reading >
Bkect61tqqoepbcvxb2j
Media

The Bioverge Podcast: Managing the Challenges of Scaling Cell and Gene Therapies

Amy DuRoss, co-founder and CEO of Vineti, sits down with Neil to discuss how the company’s platform technology addresses the unique supply chain management challenges of cell and gene therapy companies.

Continue Reading >
Prev Next